Innovation Pharmaceuticals Inc (IPIX)

[noretreat]

Thanks for the thoughtful response. There are at least 2 viewpoints on the K trial length...Your view is the "half-full" view. The "half-empty" view is more like..."If K were showing efficacy there would be more focus on it and cohorts would advance more quickly".

That is all speculative, of course, and my original post was an effort at objectivity. The realistic view is that K needs to get through at least 2 more cohorts and that plus analysis equals another year or more.

If they (D-F) would ever get around to looking at the p21 data, that would help....